3.29

4.62% -0.04

Inventiva ADR (IVA)

Overview News Price History Discussions Forecast

Inventiva ADR stock is currently priced at $3.29, with a 24-hour trading volume of 3,271. It has seen a -4.62% decreased in the last 24 hours and a -14.36% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $3.20 pivot point. If it approaches the $3.33 resistance level, significant changes may occur.

Previous Close:

$3.25

Open:

$3.18

24h Volume:

3,271

Market Cap:

$169.38M

Revenue:

$18.85M

Net Income/Loss:

$-119.67M

P/E Ratio:

-1.6193

EPS:

-2.0318

Net Cash Flow:

$-89.09M

1W Performance:

-6.06%

1M Performance:

-14.36%

6M Performance:

-16.22%

1Y Performance:

+13.97%

1D Range:

$3.11

$3.29

52W Range:

$2.43

$5.05

Inventiva ADR Stock (IVA) Company Profile

Name

Inventiva ADR

Sector

Healthcare (1191)

Industry

Biotechnology (688)

Phone

33 3 80 44 75 00

Address

50 rue de Dijon, Daix

Employee

Twitter

Next Earnings Date

Latest SEC Filings

IVA's Discussions on Twitter

Inventiva ADR Stock (IVA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-27-23	Initiated	Canaccord Genuity	Buy
May-31-23	Initiated	ROTH MKM	Buy
May-19-23	Upgrade	Societe Generale	Sell → Buy
Mar-17-23	Initiated	Stifel	Buy
Nov-15-22	Downgrade	Societe Generale	Buy → Sell
Mar-08-21	Downgrade	Societe Generale	Buy → Sell
Aug-05-20	Initiated	ROTH Capital	Buy
Aug-04-20	Initiated	Guggenheim	Buy
Aug-04-20	Initiated	Stifel	Buy

View All

Inventiva ADR Stock (IVA) Latest News

Inventiva annonce le dépôt de son Document d’Enregistrement Universel 2023 et de son Rapport Annuel 2023 (« Form 20-F »)

GlobeNewswire Inc.

Inventiva annonce la nomination d’Andre Turenne en tant qu’administrateur

GlobeNewswire Inc.

Inventiva publie ses résultats annuels 2023

GlobeNewswire Inc.

Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial Results

GlobeNewswire Inc.

Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D

GlobeNewswire Inc.

Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?

The Motley Fool

Inventiva ADR Stock (IVA) Financials Data

Inventiva ADR (IVA) Revenue 2024

IVA reported a revenue (TTM) of $18.85 million for the quarter ending December 31, 2023.

Inventiva ADR (IVA) Net Income 2024

IVA net income (TTM) was -$119.67 million for the quarter ending December 31, 2023.

Inventiva ADR (IVA) Cash Flow 2024

IVA recorded a free cash flow (TTM) of -$89.09 million for the quarter ending December 31, 2023.

Inventiva ADR (IVA) Earnings per Share 2024

IVA earnings per share (TTM) was -$2.6346 for the quarter ending December 31, 2023.

Inventiva S.A., a biopharmaceutical company, develops drugs for the treatment of fibrotic, cancer, and orphan diseases. Its lead product candidate is Lanifibranor that is in Phase IIb clinical trial to treat nonalcoholic steatohepatitis and systemic sclerosis. The company also develops Odiparcil, which is in Phase IIa clinical trial primarily for the treatment of mucopolysaccharidosis type VI disease; YAP-TEAD that is in preclinical stage to treat malignant mesothelioma and lung cancer; NSD2 for the treatment of multiple myeloma; and EPICURE for immuno-oncology treatment. It has partnership collaborations with the Institut Curie in the field of oncology; AbbVie for developing ROR? project that is used for the treatment of autoimmune diseases, as well as other projects relating to fibrosis; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.